Showing 20 of 57 recruiting trials for “Diffuse large B-cell lymphoma”
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
RecruitingNCT07335120 ↗
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
👨⚕️ qlr2007@126.com Qian, PhD, Navy General Hospital, Beijing📍 1 site📅 Started Aug 2024View details ↗
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
👨⚕️ QingQing Cai, MD. PhD., Sun yat-sen university cancer cente📍 2 sites📅 Started Aug 2024View details ↗
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
👨⚕️ Michael Dickinson, MBBS, D Med Sc, FRACP, FRCPA, Peter MacCallum Cancer Centre, Australia📍 6 sites📅 Started May 2024View details ↗
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
RecruitingNCT06294652 ↗
AGMT Austrian Lymphoma Registry
👨⚕️ Richard Greil, MD, Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg, Austria📍 1 site📅 Started Feb 2024View details ↗
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
👨⚕️ Martin Wermke, Prof., Technische Universität Dresden (TUD)📍 1 site📅 Started Feb 2024View details ↗
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
👨⚕️ Samuel Yamshon, M.D., Weill Medical College of Cornell University📍 1 site📅 Started Oct 2023View details ↗
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
👨⚕️ lugui Qiu, MD, blood diseases hospital，chinese academy of medical sciences📍 1 site📅 Started Sep 2023View details ↗
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →